RNAC
Cartesian Therapeutics, Inc.
Next earnings Aug 5, 2026 · consensus $-0.89 EPS, $137K rev
Last earnings -3.9% on 2026-04-30
$9.42
▲ +5.49%$9.42▼ -3.48%
over 1Y
L $5.84EODHDH $13.77
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+5.5%
1W-5.3%
1M+35.9%
3M+61.0%
YTD+39.3%
1Y-3.5%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 14 analysts
Buy
Conservative balance sheet (liabilities/equity -3.35x); but revenue fell -99.0% YoY.
Cartesian Therapeutics, Inc. shows $400K in FY2025 revenue (-99.0% YoY), a -32575.5% net margin.
Sources: SEC EDGAR (CIK 0001453687, latest 10-Q filed 2026-04-30) · EODHD · as of 6/26/2026, 7:09:42 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.